Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc. (ORIC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Oric is a clinical-stage biopharmaceutical company focused on overcoming resistance in cancer. The company's strategy centers on two lead clinical programs: rinzimetostat (PRC2 inhibitor for prostate cancer) and enozertinib (EGFR inhibitor for non-small cell lung cancer). In August 2025, the company announced a strategic pipeline prioritization, eliminating its discovery research group and reducing its workforce by approximately 20% to focus resources on these two lead candidates.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(129,468) | $(127,847) |
| Research & Development Expenses | $109,818 | $114,072 |
| General & Administrative Expenses | $33,186 | $28,823 |
| Cash, Cash Equivalents, and Investments | $392,250 | $255,960 |
| Accumulated Deficit | $(692,242) | $(562,774) |
| Net Cash Used in Operating Activities | $(110,970) | $(112,662) |
| Net Cash Provided by Financing Activities | $245,264 | $126,547 |
Note: The company has no debt obligations as of December 31, 2025. Liquidity is supported by cash, cash equivalents, and investments totaling approximately $392.3 million.
Material Changes vs. Prior Period
- Net Loss: Increased slightly by $1.6 million (1.3%) to $129.5 million, driven by higher personnel costs and stock-based compensation, partially offset by lower external R&D costs.
- R&D Expenses: Decreased by $4.3 million (3.7%) to $109.8 million. This reduction was due to lower drug manufacturing costs for rinzimetostat and costs from discontinued programs, offset by higher internal personnel costs ($7.5 million increase) and advancement of enozertinib.
- G&A Expenses: Increased by $4.4 million (15.1%) to $33.2 million, primarily due to higher personnel costs and professional services, including an additional $2.7 million in non-cash stock-based compensation.
- Capital Raises: Significant financing activity in 2025 included a private placement in May 2025 raising $125.0 million (gross) and ATM offerings raising approximately $117.6 million (net). In contrast, 2024 financing was limited to a January private placement of $125.0 million (gross).
- Workforce Reduction: A strategic pipeline prioritization in August 2025 resulted in a ~20% workforce reduction and a one-time cost of approximately $1.9 million for termination benefits.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Rinzimetostat (Prostate Cancer): Completed dose exploration in Phase 1b. Provisional Recommended Phase 2 Doses (RP2Ds) selected for combination with darolutamide and apalutamide. Dose optimization data expected in Q1 2026; first global Phase 3 registrational trial expected to initiate in H1 2026.
- Enozertinib (NSCLC): Selected 80 mg QD as the monotherapy dose for potential Phase 3 development. Phase 1b data in treatment-naïve and previously treated patients showed competitive systemic response rates and profound CNS activity. Data expected in H2 2026 for first-line NSCLC patients.
- Liquidity: Management believes existing cash, cash equivalents, and investments ($392.3 million) are sufficient to fund operations into the second half of 2028.
Risks and Contingencies
- Regulatory Approval: No products are approved for commercial sale. Success depends on completing clinical trials and obtaining FDA/EMA approval, which is uncertain.
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to fund development and commercialization.
- Third-Party Dependence: Reliance on third-party manufacturers for API and drug product, and third-party CROs for clinical trials. Supply chain disruptions or manufacturer failures could delay development.
- Intellectual Property: Dependence on in-licensed patents from Mirati (now BMS) and Voronoi. Risks include patent challenges, expiration, or inability to enforce rights.
- Legal Proceedings: The Chief Business Officer was found liable for insider trading in a matter unrelated to Oric (2016 transactions); the officer has appealed the decision. No material litigation currently pending against the company.
Key Facts for Investor Verification
- Cash Runway: Verify the $392.3 million cash position and the management projection of funding operations into H2 2028 against actual burn rates.
- Clinical Milestones: Monitor the Q1 2026 data readout for rinzimetostat dose optimization and the H1 2026 initiation of the Phase 3 trial.
- Enozertinib Data: Track the H2 2026 data readout for first-line NSCLC patients with EGFR exon 20 and PACC mutations.
- License Agreements: Review the terms of the Mirati (BMS) and Voronoi license agreements, specifically regarding milestone payments (up to $111M development/$225M commercial for Voronoi) and royalty obligations.
- Workforce Impact: Assess the long-term impact of the 20% workforce reduction and elimination of the discovery research group on future pipeline generation.